natgillin/translations-raw huggingface dataset:
An isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide is selected from the group consisting of peptides comprising the amino acid sequence of SEQ ID NO: 30, 19, 22, 34, or 358. 
NO:376 ili 379. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 1 78.
In the absence of endogeneous ligand or agonist, a proportion of the receptor population undergoes spontaneous allosteric transition, leading to a conformation that can bind G-proteins. 
U odsutnosti endogenog liganda ili agonista, dio receptorske populacije prolazi kroz spontanu alosteričku tranziciju, što dovodi do konformacije koja se može vezati za G-protein.
In certain such embodiments the composition comprises at least about 80% (by wt) of polyethylene oxide. The composition may also comprise at least about 85 or 90% (by wt) polyethylene oxide. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 11, naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida.
a comparator configured to compare, after the start of a race and before the end of the race, the first track segment passage results with the second track segment passage results, the second track segment passage results being a distribution profile comprising a distribution in location across the width of the sports track for the second set of at least two track segments, the distribution profile representing a number of expected participants for each track segment of the second set of the at least two track segments; an analyser configured to determine and output, after the start of a race and before the end of the race, whether the first track segment passage results deviate from the second track segment passage results by a deviation margin in order to detect an irregularity on the sports track; and 
komparator (12) je konfiguriran za uspoređivanje svakog od dobivenih brojeva prošlih sudionika uspoređivanjem svakog od dobivenih brojeva prošlih sudionika s odgovarajućim dodatnim brojem prošlih sudionika za odgovarajući dodatni segment trkačke staze; i analizator (13) je konfiguriran za detektiranje događaja na sportskoj trkačkoj stazi kada najmanje jedan od dobivenih brojeva prošlih sudionika odudara za u najmanju ruku devijacijsku marginu od dodatnog broja prošlih sudionika za odgovarajući dodatni segment trkačke staze. Računalni program, naznačen time što sadrži dijelove softverskog koda konfigurirane, prilikom instaliranja i izvršavanja u sustavu u skladu s jednim ili više patentnih zahtjeva 5-8, za provođenje bilo kojeg od postupaka u skladu s patentnim zahtjevima 1-4.
The process according to claim 33, characterised in that 0.4 by weight % of aliphatic carboxylic acid(s), based on the weight of the mineral filler in step (b), and 0.8 by weight % of Group II or Group III salt(s) of an aliphatic carboxylic acid, based on the weight of the mineral filler, in step (a). 
Postupak prema bilo kojem od zahtjeva 1 do 20, naznačen time da se 0.4 težinski % alifatske karboksilne kiseline odnosno alifatskih karboksilnih kiselina, temeljeno na težini mineralnog punila primjenjuje u koraku (b), te se 0.8, 0.6; 1.0 ili 1.2 težinski % soli Skupine II ili Skupine III alifatske karboksilne kiseline, temeljeno na težini mineralnog punila, primjenjuje u koraku (a), a poželjno 0.8 težinski %.
The composition of any of claims 3-6, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Sastav iz patentnog zahtjeva 5 ili 6, ili patentnih zahtjeva 7-10, gdje ovisno o patentnom zahtjevu 5 ili 6, nadalje obuhvaća drugi terapijski agens koristan u liječenju ili sprečavanju bolesti 1li stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih poremećaja; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
However, instead of subjecting the compound (11) to hydroboration, the 2,3-double bond is converted to an epoxide by reaction with meta -chloroperbenzoic acid (MCPBA) and perchloric acid. 
Naravno, umjesto podvrgavanja spoja (II) hidroboriranju, 2,3-dvostruka veza je prevedena u epoksid reakcijom s meta-kloroperbenzojevom kiselinom (MCPBA) i perklornom kiselinom.
The metal kegs are heavy, and thus difficult to handle, and cause excessive transportation costs. 
Metalne bačve su teške i stoga teške za rukovanje, i uzrokuju velike transportne troškove.
The use of claim 42 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, malignant ascites, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia. 
Spoj prema patentnom zahtjevu 39, naznačen time što je rak solidni tumor, sarkom, fibrosarkom, osteom, melanom, retinoblastom, rabdomiosarkom, glioblastom, neuroblastom, teratokarcinom, hematopoetski malignitet, maligni ascites, Kaposijev sarkom, Hodgkinova bolest, limfom, mijelom ili leukemija.
The method of claim 7, wherein the propyzamide is applied at a rate from 100 g ai/ha to 2240 g ai/ha and the compound of formula (I) or agriculturally acceptable salt or ester thereof is applied at a rate from 1 g ae/ha to 10 g ae/ha, preferably wherein the propyzamide is applied at a rate from 250 g ai/ha to 750 g ai/ha and the compound of formula (I) or agriculturally acceptable salt or ester thereof is applied at a rate from 1.25 g ae/ha to 10 g ae/ha. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što propizamid se primjenjuje u količini od 100 g ai/ha do 2240 g ai/ha, a spoj formule (I), ili njegovu agrikulturno prihvatljivu sol ili ester, se primjenjuje u količini od 1 g ae/ha do 10 g ae/ha, po mogućnosti gdje se propizamid primjenjuje u količini od 250 g ai/ha do 750 g ai/ha, a spoj formule (I), ili njegova agrikulturno prihvatljiva sol ili ester, se primjenjuje u količini od 1.25 g ae/ha do 10 g ae/ha.
Sulfur donors may interact with the formation and/or the reconstruction process of the nail keratin. 
Donori sumpota mogu utjecati na postupak nastanka i/ili rekonstrukcije keratina nokta.
CRL-9096 (CHOdhfr-) when expressed therein; wherein said PankoMab molecule composition is obtainable at a higher yield by producing it in the host cell DSM ACC 2806 (NM-H9D8) compared to a PankoMab molecule composition isolated from ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; gdje se navedeni pripravak s molekulom PankoMab može načiniti uz veći prinos njegovom proizvodnjom u DSM ACC 2806 (NM-H9D8) kao stanici domaćinu u usporedbi s pripravkom s molekulom PankoMab izoliranom iz ATCC No.
Hydrophobic charge-induction chromatography is a subset of HIC using resins carrying ligands such as 4-mercaptotheylpyridine derivatives. 
Kromatografija s hidrofobnom indukcijom naboja je specijalan tip HIC-a gdje se koriste nosači koji na sebi nose ligande poput derivata 4-merkaptoteilpiridina.
is a heteroaryl group, wherein said heteroaryl group is thiazolyl, oxadiazolyl or pyrimidinyl and wherein said thiazolyl, said oxadiazolyl or said pyrimidinyl has one substituent (R1), and further wherein said heteroaryl group is covalently bonded to the remainder of the molecule through a ring carbon atom; 
je monociklička heteroaril-skupina, pri čemu navedena heteroaril-skupina ima jedan supstituent (R1), i nadalje time, da je navedena heteroaril-skupina kovalentno vezana na ostatak molekule preko prstenskog atoma ugljika;
For example, the renewable fuel oil may have an ash content of less than 0.4 wt. %, such as less than 0.3 wt. %, less than 0.2 wt. %, less than 0.1 wt. %, less than 0.05 wt. %, less than 0.005 wt. %, or less than 0.0005 wt. %. 
Postupak prema jednom od zahtjeva 1 do 6, naznačen time što: 1) celulozna biomasa sadrži otpatke šećerne trske, palmino lišće ili prazne voćne grozdove; 1 1i) neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i sadržaj pepela od manje od 0,1 wt. 9%.
2, providing, as in FIG. 3, on the first waterproofing layer 15 an internally hollow structure 16 whose inner face 17, directed toward the inside of the basin, is substantially vertical, adapted to provide a substantially vertical wall of the central tank V, 
- osiguravanje na prvom vodootpornom sloju (15) unutarnje šuplje strukture (16) čija je unutarnja strana (17), usmjerena prema unuttrašnjosti osnove, supstancijalno vertikalna, prilagođena da osigurava supstancijalno vertikalni zid središnjeg spremnika (V),
is 7 amino acid residues in length; 
L; je duljine 7 ostataka amino kiseline;
Permeation enhancing agents are compounds that promote penetration and/or absorption of the buprenorphine through the skin and into the blood stream of the patient. 
Sredstva za poboljšavanje prodiranja su spojevi koji potiču prodiranje i/ili apsorpciju buprenorfina kroz kožu i u krvni optok pacijenta.
Similar results can be achieved when xanthane gum is dissolved in the pelletezing liquid, or when the pelletizing liquid contains both dimethyl polysiloxane and xanthane gum. 
Slični rezultati mogu se postići ako se ksantanska guma otopi u tekućini za granuliranje, ali ako tekućina za granuliranje sadrži dimetil polisiloksan i ksantansku gumu.
After stirring at room temperature for 18 hours, the reaction mixture was concentrated in vacuo. 
Nakon miješanja na sobnoj temperaturi tijekom 18 sati, reakcijska smjesa se koncentrira in vacuo.
“Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak debelog crijeva.
The process of claim 1, wherein Compound 3 is prepared by a process selected from the group consisting of: and, wherein: 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 3 se dobiva postupkom kojeg se bira iz skupine koju čine:
Thiazolidin-4-one derivatives according to claims 4 to 9 wherein R14 represents an unsubstituted, or a mono- or di-substituted phenyl group, substituted with methyl or halogen, and R15 represents lower alkyl. 
Derivati tiazolidin-4-ona prema zahtjevima 4 do 9, naznačeni time, da R14 predstavlja nesupstituiranu, ili a mono- ili di-supstituiranu fenilnu skupinu, supstituiranu metilom ili halogenom, a R15 predstavlja niži alkil.
wherein the DA1R358K comprises an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 1, said amino acid sequence comprising a UIM1 domain, a UIM2 domain, a LIM domain and an R to K mutation at a position equivalent to position 358 of SEQ ID NO: 1. 
obuhvaća aminokiselinsku sekvencu koja ima najmanje 50% identiteta sekvence od SEQ ID NO:1, dok navedena aminokiselinska sekvenca obuhvaća IJIMI-domenu, UIM2-domenu, LIM- domenu i mutaciju Ru K, na poziciji koja je ekvivalentna poziciji 358 od SEQID NO:1.
Device as claimed in claims 1 - 9 characterised in that said measuring unit (21) is provided with appropriate means for anchoring to the patient's body. 
Uređaj prema patentnim zahtjevima 1 - 9, naznačen time što je navedena jedinica (21) za mjerenje osigurana odgovarajućim sredstvom za pričvršćivanje za tijelo pacijenta.
The method of claim 18, wherein the reducing agent is selected from the group consisting of thioglycolic acid and its derivative salts and esters, thiolactic acid and its derivative salts and esters, cysteine and its derivatives, cysteamine and its derivatives, inorganic sulfites, sodium metabisulfite, other inorganic bisulfites, dithiothreitol, dithioerythritol, organic phosphines, and Japanese relaxers. 
Postupak prema zahtjevu 18, naznačen time da je redukcijsko sredstvo odabrano iz skupine koju čine tioglikolna kiselina i iz nje izvedene soli i esteri, tiomliječna kiselina i iz nje izvedene soli ili esteri, cistein i njegovi derivati, cisteamin i njegovi derivati, neorganski sulfiti, natrijum metabisulfit, drugi neorganski bisulfiti, ditiotreitol, ditioeritritol, organski fosfini, te japanski ispravljači.
the threonine at position 5 of the FG loop (SEQ ID NO: 75) is substituted to with an amino acid selected from the group consisting of A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W, and Y; 
treonin na položaju 5 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, V, W te Y;
Use according to claim 4, wherein said virus is selected from the group consisting of measles virus, Respiratory Syncytial Virus (RSV), mumps virus, rubella virus, Sendai virus, human para-influenza types I and III, Newcastle disease virus, Rinderpest virus, canine distemper virus, and duck para-influenza virus. 
paramiksovirus ili rekombinantni paramiksovirus izabran iz grupe koja obuhvaća virus ospica, virus zaušnjaka, rubela virus, Sendai virus, Respiratorni Sincicijski virus (RSV), humani para-influenca tipovi I i III, virus goveđe kuge, virus pseće kuge, virus Newcastle bolesti, virus pačje para-influence;
The Fc-containing molecule of embodiment 1, wherein residue 228 is mutated from S to P. 
Molekula koja sadrži Fc iz zahtjeva 1, gdje je ostatak 228 mutiran od S do P. 8.
The present invention provides an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide which comprises: an Rv2386c protein sequence; 
Izolirani polinukleotid koji ima nukleinskokiselinski slijed koji kodira polipeptid koji ima: (1) slijed proteina Rv2386c;
The process of claim 14, wherein the color of the solution of hydrobromic acid in acetic acid is less than 700 APHA. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je otopina 33%-tna bromovodična kiselina u octenoj kiselini.
optionally, if the pH of mixture is higher than pH 4.8, reducing the pH of mixture to a pH in the range of 3.0-4.8 by addition of a food acid, and packaging the mixture, 
prehrambenu kiselinu, b) izborno, ako je pH smjese veći od pH 4,8, smanjivanju pH smjese do pH u rasponu od 3,0-4,8 dodavanjem prehrambene kiseline, i
the host cell is derived from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Chrysosporium, Chaetomium, Acremonium, Candida and Yarrowina, and/or 
Stanica-domaćin u skladu s patentnim zahtjevom 11, naznačena time, da je stanica domaćin izvedena iz skupine koja se sastoji od Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penidllium, i Candida Yarrowina.
A subject of the present invention is also a compound chosen from the compound of formula (I), enantiomers thereof and pharmaceutically acceptable salts thereof, for its use in the treatment and/or prevention of rosacea. 
Spoj prema zahtjevu 1, za uporabu kao lijek. Spoj prema zahtjevu 1 ili 2, za uporabu u prevenciji i/ili liječenju rozaceje.
Citric acid was added to the aqueous solution until pH=3. 
U vodenu otopina dodaje se limunska kiselina do pH 3.
H, -halogen, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; 
H, -halogena, i [image], gdje cik-cak oznaka pokazuje točku vezanja na matičnu molekulu, pri čemu A, G i E neovisno predstavlja ugljik (supstituiran s vodikom ili izbornim supstituentima kako je naznačeno ovdje) ili dušik, pod uvjetom da najviše 2 od A, G i E su dušici;
In some embodiments, the host cell further comprises a polynucleotide encoding a prokaryotic chaperone protein (such as Dsb proteins (DsbA, DsbB, DsbC, DsbD, FkpA and/or DsbG). In some embodiments, chaperon protein is overexpressed in the host cell. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da stanica domaćina dodatno obuhvaća polinukleotid koji kodira najmanje jedan prokariotski polipeptid odabran 1z skupine koju čine DsbA, DsbC, DsbG i FkpA, ili polinukleotid koji kodira i DsbA i DsbC.
The presence of dextromethorphan decreased the IC50 of tolperisone by nearly 80% (IC50 of tolperisone alone: 52.4 µM; IC50 of tolperisone in the presence of dextromethorphan: 11.4 µM; sigmoid fitting), namely dextromethorphan multiplied the efficacy of tolperisone by a factor of five. 
Prisutnost dekstrometorfana smanjila je vrijednost ICsg tolperisona za gotovo 80% (ICso samog tolperison: 52,4, uM; ICsg tolperisona u prisutnosti dekstrometorfana: 11,4 uM; sigmoidno poklapanje), naime dekstrometorfan umnožava učinkovitost tolperisona za faktor pet.
The method of claim 1, wherein the therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a patient with a newly diagnosed proliferative disorder, to maintain remission, or a relapsed/refractory proliferative disease patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje subjektu s novodijagnosticiranom akutnom mijeloičnom Ieukemijom (AML), da bi se održala remisija ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
phenyl. The compound of claim 1 wherein R2a, R2b and R2c are independently selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1 gdje su R*", R2b i R2c nezavisno izabrani iz grupe koju čine:
The 13C NMR spectra were carried out on solutions in deuterated chloroform using a Varian Gemini NMR spectrometer (50MHz). 
*C NMR spektri su snimani u otopinama u deuteriranom kloroformu uporabom Varian Gemini NMR spektrometra (50MHz).
The method of claim 1 or 7, wherein the subject has been diagnosed with heart failure, or has a BMI of 25-29, a BMI of ≥ 30, or renal insufficiency. 
Postupak kod patentnog zahtjeva 1, gdje osoba ima BMI od 25-29, BMI od ≥ 30, ili insuficijenciju bubrega.
Use of (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (a) a B2 agonist as defined in any one of claims 1 and 3 to 6 for the treatment of a respiratory disease as defined in claim 10 or 11. 
Antagonist M3 muskarinskih receptora kako je definirano u zahtjevu 1 ili 2 za paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s P2 agonistom kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen liječenju bolesti dišnog sustava kao što je definirano u zahtjevu 7 ili 8.
The mixture can be allowed to rest following addition of all components but prior to moulding to allow air to escape from the mass. 
Smjesa može biti ostavljena da odstoji poslije dodavanja svih komponenti ali prije kalupljenja da bi sc omogućilo da zrak izađe iz masc.
The fan assembly of claim 3, wherein said portion of the base comprises a wedge. 
Ventilatorski sustav prema zahtjevu 3, gdje dio (165) baze obuhvaća zaglavak.
In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control. Aspects of the invention Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day or 1602 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 -puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
Peristaltic pump (Minipuls Gilson or equivalent); 
- - Peristaltička pumpa (Minipuls Gilson ili ekvivalent toga);
wherein the exons of said humanized CD47 gene consist of exon 1 of said mouse CD47 gene, exons 2-7 of said human CD47 gene, and the remaining exons downstream of exon 7 of said mouse CD47 gene, wherein exons 2-7 of said human CD47 gene encode amino acids 16-292 of SEQ ID NO: 10, wherein said humanized CD47 gene is under control of the endogenous mouse CD47 promoter at said endogenous mouse CD47 locus, and 
Glodavac čiji genom sadrži humanizirani gen CD47, naznačen time što humanizirani gen CD47 sadrži egzon 1 iz endogenog glodavačkog gena CD47, egzone 2-7 iz ljudskog gena CD47, te egzone nizvodno od egzona 7 iz endogenog glodavačkog gena CD47, gdje je humanizirani gen CD47 operabilno spojen s promotorom endogenog glodavčkog CD47.
the first guide is arranged to direct a roulette ball from the ball launcher into the wheel bowl in a first circumferential direction; and the second guide is arranged to direct a roulette ball from the ball launcher into the wheel bowl in a second circumferential direction, opposite to the first circumferential direction; 
prva vodilica služi za usmjeravanje kuglice za rulet od lansera kuglice u zdjelu kola u prvom obodnom smjeru; i druga vodilica služi za usmjeravanje kuglice za rulet od lansera kuglice u zdjelu kola u drugom obodnom smjeru, suprotnom prvom obodnom smjeru;
A packaging according to claim 1, wherein the inner part comprises a plurality of retaining members provided on the first and/or second side for retaining elements. 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 14 do 42, naznačeno time, što unutarnji dio sadržava veći broj članova za držanje koji su predviđeni na prvoj i/ili na drugoj strani radi držanja elemenata.
A method according to claim 7, wherein the secret is further derived from the ID code. 
Metoda u skladu s patentnim zahtjevom 7, naznačena time, da se tajnost nadalje izvodi iz ID koda.
represents a group of formula ii), wherein Z is an oxygen atom and Ra is selected from a hydrogen atom, a hydroxy group and a methyl group; or 
predstavlja grupu formule ii), pri čemu je Z atom vodika, a Ra je odabran iz atoma vodika, hidroksi grupe ili metilne grupe; ili
At this equitoxic dose, the median number of metastases seen with microaggregates was 4.5 (range 1-18), compared to 16 (range 4-57) with monomeric IL-2, with the difference being statistically significant. 
Kod ove ekvitoksične doze srednji broj metastaza opažen kod mikroagregata je bio 4,5 (opseg 1-18) u usporedbi s 16 (opseg 4-57) s monomernim IL-2, s razlikom koja je statistički značajna.